TPTX
$108.00
Turning Point Therapeutics
$1.95
1.84%
TPTX
Earnings Whisper ®
N/A
4th Quarter December 2020
Consensus:  ($0.94)
Revenue:  $0.00 Mil
Thursday
Feb 11
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when TPTX reports earnings?
Beat
Meet
Miss

Where is TPTX's stock price going from here?
Up
Flat
Down
Stock chart of TPTX
Analysts
Summary of analysts' recommendations for TPTX
Score
Grade
Pivots
Resistance
-
-
-

-

Support
-
-
-
Tweet
Growth
Description
Turning Point Therapeutics is a clinical-stage biopharmaceutical company designing and developing novel small molecule, targeted oncology therapies to address key limitations of existing therapies and improve the lives of patients. Their internally developed and wholly owned pipeline of next-generation tyrosine kinase inhibitors (TKIs) targets numerous genetic drivers of cancer in both TKI-na?ve and TKI-pretreated patients. The pervasive challenges of intrinsic and acquired treatment resistance often limit the response rate and durability of existing therapies. One of these challenges is the emergence of solvent front mutations, which are a common cause of acquired resistance to currently approved therapies for ROS1, TRK and ALK kinases. They have developed a macrocycle platform enabling us to design proprietary small, compact TKIs with rigid three-dimensional structures that potentially bind to their targets with greater precision and affinity than other kinase inhibitors.